Approximately 30 percent of men treated for PCa with surgery or radiation have evidence of recurrent disease, and in a subset of men, levels of prostate-specific antigen (PSA) continues to rise after treatment [3]. The gene discussed is PROS1; the disease is posterior cortical atrophy.